-

SpineX Announces Successful in-Human Results to Treat Adults with Cerebral Palsy

First in-human study using its proprietary non-surgical and non-invasive SCiP device to treat adults with Cerebral Palsy shows marked patient improvement after just eight weeks

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc. today announced groundbreaking results in its first in-human study treating an adult with Cerebral Palsy (CP). The study, published in the esteemed medical journal BioElectronic Medicine, demonstrates significant functional improvements in an adult with CP after treatment with the company’s proprietary non-surgical SCiP™ therapy.

Led by Drs. Rahul Sachdeva, PhD and Kristin Girshin, PT, DPT, this study affirms how after just eight weeks of SCiP therapy treatment, a 60-year-old woman living with CP is able to perform daily living activities with minimal external assistance. “This is an absolute game changer for the CP community,” says the patient, who has lived with CP her entire life. Despite living with this severely debilitating condition, she has managed her symptoms with current standard of care therapies. However, she consistently encountered limited mobility and spent a great deal of energy completing routine tasks.

“After eight weeks of SCiP therapy, my balance was better, I was more confident in walking and climbing stairs with minimal assistance and was able to get dressed in less than half my usual time,” she says. “Over the years, I’ve tried every possible therapy available, but none of them had the impact that SCiP had, and in such a short period of time.”

SpineX has Breakthrough Device Designation (BDD) from the US FDA for SCiP and its proposed treatment of CP. SpineX has also engaged with the FDA to align on a proposed clinical trial to be conducted later this year, with the results expected to lead to FDA clearance of the SCiP device for the treatment of CP. “SCiP is a key missing piece in the puzzle for the treatment of CP,” says Dr. Girshin, lead therapist for the study and a key opinion leader within the CP community. “I am excited by the potential impact that SCiP could have on the CP population for both adults and children.”

About SpineX Inc.

SpineX Inc. is a clinical stage bioelectric MedTech company developing noninvasive spinal cord neuromodulation devices as a platform technology. SCONE™ and SCiP™ are two FDA-designated Breakthrough Devices being developed by SpineX for the treatment of adults with Neurogenic Bladder and Children with Cerebral Palsy respectively. SCONE™ and SCiP™ are investigational devices and are limited by Federal (USA) law to investigational use only. FDA has not yet reviewed the safety and effectiveness of SCONE™ and SCiP™. Visit www.spinex.co to learn more about SpineX Inc.

Contacts

Jennifer Boon
media@spinex.co

SpineX Inc.


Release Versions

Contacts

Jennifer Boon
media@spinex.co

More News From SpineX Inc.

SpineX Inc. Announces Significant Improvement in Urinary Bladder Function in Paralyzed Individuals with SCONE™ Therapy

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc., a pioneering medical technology company developing innovative non-surgical spinal cord neuromodulation solutions, today announced the results of its global, multisite pivotal trial, CONTINENCE, evaluating the safety and efficacy of SCONE™ therapy for neurogenic bladder (NB) in individuals with paralysis due to spinal cord injury (SCI), stroke, or multiple sclerosis (MS). The study demonstrated a statistically significant improvement in NB symptoms in t...

SpineX Closes Recruitment for SCONE™ Clinical Trial

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device. The clinical trial—Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Clinical Study— began in May 2022. SCONE is an innovative device that treats urinary incontinence allowing people living with neurogenic bladder due to spinal cord injury, multiple sclerosis, or stroke to live life on their own terms. SpineX scientists and resea...

SpineX close to full recruitment for SCONE™ clinical trial

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc. is today announcing close to full recruitment -- over 80% -- of the patient cohort for its clinical trial of its proprietary SCONE™ device. SCONE is an innovative device that treats urinary incontinence allowing people living with neurogenic bladder due to spinal cord injury, multiple sclerosis, or stroke to live life on their own terms. The clinical trial—Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Cl...
Back to Newsroom